MEI Pharma Inc.: Diferență între versiuni
The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).
Admin (discuție | contribuții) (Pagină nouă: Pagina dedicata companiei MEI Pharma Inc. listata cu simbolul US.MEIP ==Descriere companie== MEI Pharma, Inc. (https://www.meipharma.com/) is a late-stage pharmaceutical company. The Company is focused on development and commercialization of novel cancer therapies. The Company's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor for the t...) |
(The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).) |
||
| Linia 1: | Linia 1: | ||
Pagina dedicata companiei MEI Pharma Inc. listata cu simbolul US.MEIP | Pagina dedicata companiei MEI [[PHARMA|Pharma]] Inc. listata cu simbolul US.MEIP | ||
==Descriere companie== | ==Descriere companie== | ||
MEI Pharma, Inc. (https://www.meipharma.com/) is a late-stage pharmaceutical company. The Company is focused on development and commercialization of novel cancer therapies. The Company's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) delta inhibitor for the treatment of B-cell malignancies. The Company is conducting Phase II study evaluating zandelisib as a monotherapy in patients with r/r FL and marginal zone lymphoma (MZL) patients who have received at least two prior lines of treatment. Its Voruciclib an oral cyclin-dependent kinase 9(CDK9) inhibitor for the treatment of myeloid leukemia and B-cell malignancies. Its ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation (OXPHOS). Its Pracinostat is an oral histone deacetylase (HDAC) inhibitor being evaluated in a Phase II trial in patients with high or very high-risk myelodysplastic syndrome (MDS). | MEI Pharma, Inc. (https://www.meipharma.com/) is a late-stage pharmaceutical company. The Company is focused on development and commercialization of novel cancer therapies. The Company's portfolio of clinical drug candidates includes Zandelisib (f/k/a ME-401), Voruciclib, ME-344, and Pracinostat. Its Zandelisib is an oral phosphatidylinositol 3-kinase (PI3K) [[DELTA|delta]] inhibitor for the treatment of B-cell malignancies. The Company is conducting Phase II study evaluating zandelisib as a monotherapy in patients with r/r FL and marginal zone lymphoma (MZL) patients who have received at least two prior lines of treatment. Its Voruciclib an oral cyclin-dependent kinase 9(CDK9) inhibitor for the treatment of myeloid leukemia and B-cell malignancies. Its ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation (OXPHOS). Its Pracinostat is an oral histone deacetylase (HDAC) inhibitor being evaluated in a Phase II trial in patients with high or very high-risk myelodysplastic syndrome (MDS). | ||
==Grafic actiuni companie== | ==Grafic actiuni companie== | ||